3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Recurrence
1
Prostatic Neoplasms
1
Osteosarcoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Lymphoma, T-Cell, Peripheral
1
Liposarcoma
1
Immunoblastic Lymphadenopathy
1
Carcinoma in Situ
1
Breast Neoplasms
1
Advanced Solid Tumor Cancer
1
Interventions
pembrolizumab
96
Carboplatin
67
Paclitaxel
56
Cyclophosphamide
40
Capecitabine
30
Specimen Handling
28
sacituzumab govitecan
26
130-nm albumin-bound paclitaxel
25
Gemcitabine
22
Magnetic Resonance Spectroscopy
21
olaparib
20
Doxorubicin
20
Albumin-Bound Paclitaxel
20
Taxes
19
Biopsy
19
Drug Therapy
16
atezolizumab
14
Nivolumab
14
toripalimab
12
Radiotherapy
12
Epirubicin
12
durvalumab
11
Docetaxel
10
Cisplatin
10
Bevacizumab
10
eribulin
9
fludarabine
8
Standard of Care
7
Radiation
7
Injections
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
Clinical Trials, Phase II as Topic
×
1 year
×
Clear all
NCT05491083
2025-07-25
ComPACT
National University Hospital, Singapore
Phase 1/2
Recruiting
51 enrolled